erbB-2, p53, and efficacy of adjuvant therapy in lymph node positive breast cancer

被引：0
|
作者：
Cameron, DA [1 ]
Leonard, RCF [1 ]
机构：
[1] Western Gen Hosp, Dept Oncol, Edinburgh EH4 2XU, Midlothian, Scotland
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1999年 / 91卷 / 08期
关键词：
D O I：
10.1093/jnci/91.8.728
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：728 / 728
页数：1
相关论文
共 50 条
  • [1] erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
    Thor, AD
    Berry, DA
    Budman, DR
    Muss, HB
    Kute, T
    Henderson, IC
    Barcos, M
    Cirrincione, C
    Edgerton, S
    Allred, C
    Norton, L
    Liu, ET
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18): : 1346 - 1360
  • [2] ErbB-2 and breast cancer: toward a personalization of adjuvant therapy?
    Zelek, L
    BULLETIN DU CANCER, 1998, 85 (11) : 922 - 923
  • [3] The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer
    Bull, SB
    Ozcelik, H
    Pinnaduwage, D
    Blackstein, ME
    Sutherland, DAJ
    Pritchard, KI
    Tzontcheva, AT
    Sidlofsky, S
    Hanna, WM
    Qizilbash, AH
    Tweeddale, ME
    Fine, S
    McCready, DR
    Andrulis, IL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 86 - 96
  • [4] p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer
    Tetu, B
    Brisson, J
    Plante, V
    Bernard, P
    MODERN PATHOLOGY, 1998, 11 (09) : 823 - 830
  • [5] P53 expression and the result of adjuvant therapy of breast cancer
    Stal, O.
    Stenmark, Askmalm M.
    Wingren, S.
    Rutqvist, L.E.
    Skoog, L.
    Ferraud, L.
    Sullivan, S.
    Carstensen, J.
    Nordenskjold, B.
    Acta Oncologica, 34 (06):
  • [6] No Gains in Efficacy Observed by Adding Gemcitabine to Adjuvant Therapy for Lymph Node-Positive Breast Cancer
    Barton, Mary Kay
    CA-A CANCER JOURNAL FOR CLINICIANS, 2014, 64 (01) : 1 - 2
  • [7] Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients - The role of p53
    Rahko, E
    Blanco, G
    Bloigu, RB
    Soini, Y
    Talvensaari-Mattila, A
    Jukkola, A
    BREAST, 2006, 15 (01): : 69 - 75
  • [8] erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
    Paik, SM
    Bryant, J
    Park, CH
    Fisher, B
    Tan-Chiu, E
    Hyams, D
    Fisher, ER
    Lippman, ME
    Wickerham, DL
    Wolmark, N
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18): : 1361 - 1370
  • [9] BREAST-CANCER RESPONSE TO ADJUVANT CHEMOTHERAPY IN CORRELATION WITH ERBB2 AND P53 EXPRESSION
    JACQUEMIER, J
    PENAULTLLORCA, F
    VIENS, P
    HOUVENAEGHEL, G
    HASSOUN, J
    TORRENTE, M
    ADELAIDE, J
    BIRNBAUM, D
    ANTICANCER RESEARCH, 1994, 14 (6B) : 2773 - 2778
  • [10] OVEREXPRESSION OF P53 IN NODE-POSITIVE BREAST-CANCER
    ALLRED, DC
    CLARK, GM
    FUQUA, SAW
    ELLEDGE, RM
    OSBORNE, CK
    LABORATORY INVESTIGATION, 1994, 70 (01) : A12 - A12
12345